Drug Profile

Research programme: gene therapeutics - Codexis/Takeda

Latest Information Update: 20 Mar 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Codexis
Class Gene therapies
Mechanism of Action Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Haemophilia A; Lysosomal storage diseases

Most Recent Events

31 Jul 2023 Codexis terminates investment in development of biotherapeutics assets, including candidates for the treatment of Fabry disease and Pompe disease, which included in the Takeda Agreement in July 2023
31 Jul 2023 Discontinued - Preclinical for Haemophilia A in USA (Parenteral) in July 2023
31 Jul 2023 Discontinued - Preclinical for Lysosomal storage diseases in USA (Parenteral) in July 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com